Plain-English translation of NCT05469165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
After a heart attack, some people develop a condition where the mitral valve (which controls blood flow in the heart) doesn't close properly, leading to serious complications. This trial tests whether a medication called cyproheptadine can prevent this problem by stopping harmful changes to the valve tissue. Researchers believe this medication might help your heart valve adapt better after a heart attack and reduce the development of valve leakage.
Mitral valve problems after a heart attack are common and serious, often leading to worsening heart failure and increased risk of death. Currently, there are limited treatments available to prevent this complication, so this trial is testing whether this medication could offer a new preventive approach.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo (a pill with no active ingredient), taken by mouth three times a day for three months. The dose may be gradually increased if you tolerate it well. Throughout the study, you'll have heart imaging tests (ultrasound and MRI scans) to monitor how your heart and valve are responding. The trial will track whether the medication helps prevent valve problems and slows the remodeling of your heart.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Canada
Phase
Testing effectiveness
Sponsor
Laval University
Collaborators
Canadian Institutes of Health Research (CIHR)
Enrollment target
~214 participants
Started
June 2023
Primary completion
September 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jonathan Beaudoin, MD
Laval University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.